Saturday 17 October 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
In the quarter to June 2026, EPS fell 34.5% and free cash flow fell 29.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
49.61
1.10
−2.17%
Follow MBX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(24.43%) | (27.76%) | (25.73%) | (33.17%) | |
| (23.59%) | (26.61%) | (24.79%) | (31.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(20.78%) | (23.58%) | (19.81%) | (25.51%) | |
Free Cash Flow per Share |
(2.31) | (2.24) | (1.71) | (1.79) | |
Free Cash Flow |
(78.91) | (81.88) | (79.81) | (85.20) | |
Capital Expenditures |
(1.23) | (1.93) | (2.34) | (2.53) | |
| Other line items | |||||
Cash ROIC |
(10.13%) | (11.02%) | (9.09%) | (10.29%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.97 | 0.92 | 0.89 | 0.79 | |
Depreciation/Fixed assets |
0.12 | 0.09 | 0.08 | 0.05 | |
Capex/Depreciation |
(4.99) | (7.78) | (9.94) | (10.00) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.27) | (2.19) | (1.66) | (1.73) | |
Capex per Share |
(0.04) | (0.05) | (0.05) | (0.05) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates